FMNL2 (Formin-like 2) is a member of the formin family of proteins, which are key regulators of actin cytoskeleton dynamics. It plays a critical role in cellular processes such as cell motility, membrane trafficking, cytokinesis, and cell adhesion by promoting actin polymerization and microtubule organization. FMNL2 is expressed in various tissues, with higher levels observed in immune cells, the brain, and epithelial tissues. Dysregulation of FMNL2 has been implicated in pathological conditions, including cancer metastasis, immune disorders, and neurological diseases, due to its influence on cell invasion and signaling pathways.
FMNL2 antibodies are essential tools for studying the expression, localization, and function of FMNL2 in both physiological and disease contexts. These antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to detect FMNL2 isoforms, quantify protein levels, or map interaction networks. Specificity and validation are critical, as FMNL2 shares structural homology with other formin family members (e.g., FMNL1 and FMNL3). High-quality antibodies are often validated using knockout cell lines or siRNA-mediated knockdown to confirm target selectivity. Research utilizing FMNL2 antibodies has advanced our understanding of its role in cytoskeletal remodeling, tumor microenvironments, and immune cell activation, highlighting its potential as a therapeutic target or biomarker in diseases like colorectal cancer and glioblastoma.